Changes to the statutory scheme to control the costs of branded health service medicines

Closed 18 Sep 2018

Opened 7 Aug 2018


The statutory scheme for pharmaceutical pricing safeguards the financial position of the NHS by limiting the cost of branded health service medicines for companies who choose not to join the accompanying voluntary Pharmaceutical Price Regulation Scheme (PPRS).

The current voluntary scheme expires on 31 December 2018. Negotiations are underway on a successor. Concurrently, the Government is proposing to amend the Branded Health Service Medicines (Costs) 2018 Regulations to alter the statutory scheme from 1 January and we are seeking views on proposals regarding:

  • Changing the payment percentage;
  • Changing the application of the payment system for sales of medicines supplied under a contract with a contracting authority based on a framework agreement or under a public contract; and
  • Including all biological medicinal products (including biosimilars) within the scope of health service medicines captured by the payment mechanism, price controls and information requirements.

Please read the consultation document and draft Impact Assessment before responding to this consultion. These documents are available at:

The consultation will run for 6 weeks and close at 23:59 on 18 September 2018. The timing ensures there is enough time to complete the required parliamentary process as well as providing a sufficent period for consultees to consider responses. You will be asked a series of questions and required to input your responses either by clicking the corresponding button or by typing in responses where this is appropriate.

What Happens Next

We will evaluate your views and any additional evidence provided to finalise our proposals. A response to this consultation will be published on GOV.UK and amendments to Regulations made in Parliament in December 2018, so that a revised statutory scheme can begin from 1 January 2019.


  • NHS Commissioning Board
  • Clinical Commissioning Groups
  • patient groups and patient advocates
  • Members of the public
  • Patients
  • Suppliers


  • Regulation